GeoVax Labs (GOVX) Q2 2024 earnings summary

Executive summary

• Secured a BARDA Project NextGen award exceeding $350 million to support a 10,000-patient Phase 2b trial of GEO-CM04S1, a next-generation COVID-19 vaccine, with Allucent as CRO partner.

• Advanced Gedeptin to a Phase 2 trial for first recurrent head and neck cancer, with trial activation anticipated in H1 2025 and plans to combine with an immune checkpoint inhibitor.

• Achieved key milestones in vaccine manufacturing, including the first commercial lot of GEO-CM04S1 and technology transfer to Oxford Biomedica.

• Focused on developing innovative cancer therapies and infectious disease vaccines for unmet medical needs, with ongoing business development and partnership initiatives.

• No product revenue to date; operations funded by equity offerings, government contracts, and grants.

Financial highlights

• Reported $301,000 in Q2 2024 revenue from the BARDA contract, marking the first billing under this award.

• Net loss for Q2 2024 was $5.06 million ($1.99/share), down from $5.93 million ($3.79/share) in Q2 2023; six-month net loss was $10.91 million ($4.68/share), compared to $9.97 million ($5.66/share) in 2023.

• R&D expenses for Q2 2024 were $4.28 million, slightly down from $4.72 million in Q2 2023; six-month R&D expenses rose to $8.7 million, up 15% year-over-year.

• General administrative expenses decreased 13% to $2.5 million for the first half of 2024, with Q2 2024 G&A at $1.09 million, down from $1.46 million in Q2 2023.

• Cash balance at June 30, 2024 was $1.56 million, with an additional $2.8 million raised in July not reflected in the Q2 balance sheet.

Outlook and guidance

• BARDA Project NextGen program is fully funded, with expected federal support between $367 million and $388 million over several years.

• Existing cash is insufficient to fund operations beyond Q3 2024; additional capital is being actively pursued through equity, debt, grants, or partnerships.

• Anticipates activating the Gedeptin Phase 2 trial in H1 2025, with ongoing planning for protocol, manufacturing, and CRO selection.

• Multiple clinical data readouts for GEO-CM04S1 expected in the second half of 2024.

• Management believes additional capital can be secured but cannot fully alleviate substantial doubt about going concern status.